One plausible explanation is that mutations in epigenetic modifiers (e.g. DNMT3A) are likely initiating events (Dai et al. 2017), whereas those in signaling genes (e.g. FLT3) drive rapid tumor growth, resulting in diagnosis with fewer subsequent mutations (Miles et al. 2020). This evidence concerns the gene FLT3 and neoplasm.